Bessemer Group
UTHR icon

Bessemer Group’s United Therapeutics UTHR Stock Holding History

Bessemer Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$691K Buy
1,275
+28
+2% +$15.8K ﹤0.01% 1085
2026
Q1 		$739K Buy
1,247
+100
+9% +$49.8K ﹤0.01% 1026
2025
Q4 		$558K Buy
1,147
+21
+2% +$9.78K ﹤0.01% 1106
2025
Q3 		$472K Buy
1,126
+28
+3% +$9.42K ﹤0.01% 875
2025
Q2 		$315K Sell
1,098
-1,768
-62% -$528K ﹤0.01% 980
2025
Q1 		$884K Sell
2,866
-6,047
-68% -$2.07M ﹤0.01% 742
2024
Q4 		$3.15M Sell
8,913
-48
-0.5% -$17.6K 0.01% 549
2024
Q3 		$3.21M Buy
8,961
+8,909
+17,133% +$3.01M 0.01% 563
2024
Q2 		$17K Hold
52
– – ﹤0.01% 1418
2024
Q1 		$12K Sell
52
-4,189
-99% -$945K ﹤0.01% 1525
2023
Q4 		$932K Sell
4,241
-427
-9% -$98.4K ﹤0.01% 672
2023
Q3 		$1.05M Buy
4,668
+28
+0.6% +$6.45K ﹤0.01% 613
2023
Q2 		$1.02M Buy
4,640
+38
+0.8% +$8.42K ﹤0.01% 634
2023
Q1 		$1.03M Sell
4,602
-2
-0% -$493 ﹤0.01% 580
2022
Q4 		$1.28M Buy
4,604
+30
+0.7% +$7.57K ﹤0.01% 531
2022
Q3 		$958K Buy
4,574
+153
+3% +$34.2K ﹤0.01% 589
2022
Q2 		$1.04M Hold
4,421
– – ﹤0.01% 565
2022
Q1 		$793K Buy
4,421
+1,351
+44% +$257K ﹤0.01% 524
2021
Q4 		$663K Buy
3,070
+1,120
+57% +$220K ﹤0.01% 559
2021
Q3 		$360K Buy
1,950
+50
+3% +$9.85K ﹤0.01% 642
2021
Q2 		$341K Hold
1,900
– – ﹤0.01% 664
2021
Q1 		$318K Sell
1,900
-52
-3% -$8.67K ﹤0.01% 651
2020
Q4 		$296K Buy
1,952
+52
+3% +$6.82K ﹤0.01% 642
2020
Q3 		$192K Sell
1,900
-6,876
-78% -$754K ﹤0.01% 735
2020
Q2 		$1.06M Buy
+8,776
New +$987K ﹤0.01% 754
2019
Q1 		– Sell
-109
Closed -$12K – 1976
2018
Q4 		$12K Hold
109
– – ﹤0.01% 1624
2018
Q3 		$14K Buy
+109
New +$13.5K ﹤0.01% 1551
2017
Q4 		– Sell
-135
Closed -$16K – 1829
2017
Q3 		$16K Sell
135
-135
-50% -$17.2K ﹤0.01% 1530
2017
Q2 		$35K Buy
+270
New +$33.7K ﹤0.01% 1375
2016
Q2 		– Sell
-8,500
Closed -$947K – 1453
2016
Q1 		$947K Buy
+8,500
New +$1.08M 0.01% 474
2015
Q4 		– Sell
-425
Closed -$56K – 1727
2015
Q3 		$56K Sell
425
-2
-0.5% -$321 ﹤0.01% 936
2015
Q2 		$75K Sell
427
-4,623
-92% -$832K ﹤0.01% 900
2015
Q1 		$871K Buy
5,050
+4,650
+1,163% +$709K ﹤0.01% 537
2014
Q4 		$52K Sell
400
-11,773
-97% -$1.52M ﹤0.01% 930
2014
Q3 		$1.57M Hold
12,173
– – 0.01% 406
2014
Q2 		$1.08M Hold
12,173
– – 0.01% 440
2014
Q1 		$1.15M Sell
12,173
-130
-1% -$13.3K 0.01% 408
2013
Q4 		$1.39M Hold
12,303
– – 0.01% 399
2013
Q3 		$970K Sell
12,303
-13,077
-52% -$956K 0.01% 417
2013
Q2 		$1.67M Buy
+25,380
New +$1.63M 0.02% 316

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Bessemer Group's UTHR Position: Q2 2026 in Review

Bessemer Group increased its United Therapeutics (UTHR) stake by 2.2% in Q2 2026, buying an estimated $15.8K and bringing the position to 1,275 shares worth $691K. The position accounts for ﹤0.01% of the portfolio, ranked #1085.

Bessemer Group first reported a position in UTHR in Q2 2013 and has held it in 40 quarters since. The position peaked at $3.21M in Q3 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Bessemer Group held 1,275 shares of United Therapeutics worth $691K as of Q2 2026.
  • Bessemer Group bought 28 United Therapeutics shares in Q2 2026, an estimated $15.8K.
  • United Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1085 holding.
  • Bessemer Group first reported a position in United Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Bessemer Group's United Therapeutics position peaked at $3.21M in Q3 2024.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.